Project Grant R01AI192359
- The National Institute of Allergy and Infectious Diseases awarded the University of North Carolina at Chapel Hill $3,064,333 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research investigating how the host immune response influences methicillin-resistant Staphylococcus aureus susceptibility to antibiotics in skin and soft tissue infections. The research comprises three specific aims. Aim 1 examines how neutrophils enriched during the...
- The National Institute of Allergy and Infectious Diseases awarded the University of Notre Dame DU Lac $748,964 on May 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop boron-based small-molecule inhibitors that restore antibiotic sensitivity in methicillin-resistant Staphylococcus aureus (MRSA). The research targets the BlaR protein, a β-lactam sensor on the bacterial cell membrane that triggers antibiotic resistance when activated. Designer boronate...
- The National Institute of Allergy and Infectious Diseases awarded $440,908 to the University of Illinois on February 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop extracellular vesicle-inspired nano vesicles for CRISPR-based targeting of methicillin-resistant Staphylococcus aureus (MRSA). The project addresses antibiotic resistance in MRSA strains, the leading cause of healthcare-associated infections in the United States and globally. Current...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $155,500 on August 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate heterogeneity in Staphylococcus aureus virulence factor activity within neutrophils and its impact on bacterial survival and host-pathogen interactions. The research examines how an isogenic population of S. aureus generates bacteria with divergent outcomes upon interaction with...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Michigan $186,758 on February 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on infection-induced cell cycle diversion and macrophage inflammatory biogenesis. The award funds investigation into how bacterial infection of macrophages, specifically by methicillin-resistant Staphylococcus aureus (MRSA), triggers structural and biochemical...
- The National Institute of Allergy and Infectious Diseases awarded $130,199 to the University of California, San Diego on December 23, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate macrophage membrane-coated nanoparticles (MF-NPs) as adjuvant therapy for severe bacterial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA). The research comprises two aims: testing in vitro whether MF-NPs modulate neutrophil responses to MRSA and...
- The National Institute of Allergy and Infectious Diseases awarded Rutgers The State University of New Jersey $762,847 on February 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the contribution of Type III interferons to the pathogenesis of Staphylococcus aureus infection. The research examines how Type III interferon signaling influences S. aureus pneumonia pathogenesis and bacterial clearance from the airway. The work includes investigation...
- The National Institute of Allergy and Infectious Diseases awarded Northwestern University $549,246 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to fund Project Grant R01AI192692, which investigates substrate selectivity and regulation of YHAM, a 3'-5' exonuclease in Methicillin-resistant Staphylococcus aureus (MRSA). The research examines how YHAM, an understudied bacterial enzyme required for MRSA virulence, functions through an unusual...
- The National Institute of Allergy and Infectious Diseases awarded Louisiana State University $599,480 on June 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the regulation of neutrophil endoplasmic reticulum stress response by IRE1A in bacterial lung infection. The research addresses innate immune mechanisms that defend against methicillin-resistant Staphylococcus aureus (MRSA) lung infection, a drug-resistant pathogen causing mortality rates up...
- The National Institute of Allergy and Infectious Diseases awarded the University of Nebraska $137,005 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate host immune and metabolic determinants of Staphylococcus aureus persister survival. The research examines how S. aureus persister cells—dormant bacterial populations that survive antibiotic therapy—interact with the host immune system and evade antimicrobial responses. Aim 1 defines...
The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded Indiana University Indianapolis $673,584 on September 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize methicillin-resistant Staphylococcus aureus (MRSA) infection dynamics in renal tissue and identify therapeutic strategies to disrupt kidney colonization during bloodstream infection. The research will define the molecular and cellular basis of MRSA persistence in the kidney through two specific aims. The first aim will characterize the spatiotemporal dynamics of MRSA invasion and host immune responses in the renal medulla using dual-species RNA sequencing, spatial transcriptomics, and multiplexed imaging, and will test the effects of modulating medullary osmolality. The second aim will determine how tissue polyamines influence MRSA tolerance to renal osmotic stress through in vivo interventions and in vitro assays controlling host and bacterial factors. The research responds to the finding that the inner medulla, where urine is concentrated, serves as an initial protected niche for MRSA invasion due to minimal early neutrophil responses, and that basal tissue polyamines enhance MRSA's ability to withstand the renal environment's extreme osmolality, elevated urea and salt levels, and acidosis. Performance will be conducted in Indianapolis, Indiana. The period of performance extends from the award date through August 31, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $673.6k | 9/2/26 |